Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03401788
Recruitment Status : Active, not recruiting
First Posted : January 17, 2018
Last Update Posted : August 23, 2021
Sponsor:
Information provided by (Responsible Party):
Peloton Therapeutics, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : March 29, 2026
Estimated Study Completion Date : March 29, 2026